Skip to content Skip to footer
Subscribe Now

NEWS

Astrazeneca
AstraZeneca Reports P-III (LOGOS & KALOS) Trial Findings of Breztri Aerosphere for Uncontrolled Asthma
Shots: AstraZeneca has reported P-III (LOGOS & KALOS) trial results evaluating Breztri Aerosphere (BGF; 320/28.8/9.6μg or 320/14.4/9.6μg) vs PT009 (ICS/LABA via Aerosphere) & Symbicort pressurized metered-dose inhaler (pMDI) in pts (n=~4400) with uncontrolled asthma Trial met its 1EP, with BGF 320/28.8/9.6μg showing significant improvement in forced expiratory volume in 1 second (FEV1) AUC 0 to 3hrs. at…
May 2, 2025
Merck Animal Health & AmacaThera
Merck Animal Health Collaborates with AmacaThera to Develop Long-Acting Injectable Formulations for Veterinary Use
Shots: Merck Animal Health has entered into a binding evaluation & option agreement with AmacaThera to develop long-acting formulations for veterinary use Collaboration will leverage AmacaThera’s AmacaGel hydrogel platform to develop single-injection veterinary therapeutics with enhanced sustained drug delivery AmacaGel is a fast-gelling hydrogel composed of 2 established polymers, designed to liquefy under shear force…
May 2, 2025
Bavarian Nordic
Bavarian Nordic Reports the MHRA’s Approval of Vimkunya to Prevent Chikungunya
Shots: The UK’s MHRA has approved Vimkunya for active immunization against CHIKV disease in individuals (≥12yrs.); launch expected in the summer of 2025. Application submitted to Health Canada, with potential approval anticipated in H1’26 Approval was based on 2 P-III trials (n>3,500) that met their 1EP of rapid immune response within 1wk., with 97.8% of…
May 2, 2025
Brightseed and Haleon
Brightseed and Haleon Collaborate to Discover Small Molecule for Human Health Innovation by Leveraging AI Platform Forager
Shots: Haleon and Brightseed have partnered to accelerate the discovery of plant-based bioactive compounds using Brightseed’s AI platform, Forager, supporting Haleon to create innovative health solutions Forager will be directly accessible to Haleon scientists, enabling AI-powered identification of natural compounds and their health-related mechanisms, streamlining R&D and product development Forager bioactive discovery has already demonstrated…
May 2, 2025
Vertex Pharmaceuticals
Vertex Pharmaceuticals’ Alyftrek Receives the CHMP’s Positive Opinion for the Treatment of Cystic Fibrosis
S R Shots:    The CHMP has recommended Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) to treat patients (≥6yrs.) with cystic fibrosis (CF), having at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Alyftrek is approved in the US and UK and is under review in Canada, Switzerland, Australia, and New Zealand Vanzacaftor &…
May 1, 2025
Load more